UKHSA announces new effort to tackle hepatitis C
The agency has launched a whole genome sequencing service to monitor the virus
Read More
Tag: HCV
MSD’s HCV report calls for key elimination boosts
The advice includes a national rollout of the HCV GP champion programme and further testing
Read More
Westminster Drug Project and Gilead Sciences join forces to take on hepatitis C
The companies have partnered for a second time to support sector-wide efforts to eliminate hepatitis C virus in drug and alcohol services
Read More
US nod for Gilead’s pan-genotypic hep C pill
The US Food and Drug Administration has waved through Gilead’s new hepatitis C therapy Vosevi, offering adults with all genotypes of the condition a new treatment option in the form of three medicines in a single pill.
Read More
UK patients get early access to AbbVie’s hepatitis regimen
AbbVie’s glecaprevir/pibrentasvir (G/P) has become the first treatment for chronic hepatitis C to be included in the UK’s Early Access to Medicines Scheme (EAMS).
Read More
US clears Gilead’s pan-genotypic hepatitis C therapy
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by the US Food and Drug Administration to treat all six types of the virus, potentially eliminating the need for genotype testing.
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
